Stockscreener 앱 받기
4.635
0.32%
-0.015
Polypid Ltd 주식(PYPD)의 최신 뉴스
Why analysts remain bullish on PolyPid Ltd. stockQuarterly Risk Review & High Conviction Buy Zone Alerts - ulpravda.ru
Aug Big Picture: Can PolyPid Ltd. stock hit analyst price targetsJuly 2025 Earnings & Intraday High Probability Setup Alerts - ulpravda.ru
Will PolyPid Ltd. stock keep outperforming rivals2026 world cup usa national team group stage young talents high defensive line odds analysis expert opinion - ulpravda.ru
PolyPid Ltd. (NASDAQ:PYPD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PolyPid Ltd. (PYPD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Moves: Can PolyPid Ltd stock sustain free cash flow growthForecast Cut & Accurate Entry/Exit Alerts - moha.gov.vn
Contrasting PolyPid (NASDAQ:PYPD) & Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
PolyPid Calls February 2026 Extraordinary Meeting to Approve Board Chair Compensation - TipRanks
PolyPid files for secondary offering - MSN
PolyPid Ltd. (NASDAQ:PYPD) Short Interest Up 72.2% in December - MarketBeat
Value Recap: Will PolyPid Ltd. stock keep outperforming rivals2025 Market WrapUp & Stock Market Timing Techniques - Улправда
Will PolyPid Ltd. stock outperform international peersMarket Growth Review & Real-Time Volume Analysis Alerts - Улправда
Can PolyPid Ltd. stock sustain free cash flow growthQuarterly Growth Report & Step-by-Step Trade Execution Guides - DonanımHaber
Why PolyPid Ltd. stock attracts global investors2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - Улправда
Why PolyPid Ltd. stock could see breakout soonQuarterly Trade Review & Comprehensive Market Scan Insights - Улправда
PolyPid Appoints Brooke Story as Chairman Amid Strategic Growth - The Globe and Mail
Polypid names medtech veteran Brooke Story as board chairman - marketscreener.com
PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors - Quiver Quantitative
PolyPid (PYPD) appoints medtech veteran Brooke Story as board chairman - Stock Titan
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets
Transcript : PolyPid Ltd.Special Call - marketscreener.com
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD) - TradingView — Track All Markets
PolyPid receives FDA support for D-PLEX100 NDA submission By Investing.com - Investing.com Australia
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA - FinancialContent
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com Nigeria
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 By Investing.com - Investing.com South Africa
PolyPid receives FDA support for D-PLEX100 NDA submission - Investing.com
PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission - marketscreener.com
Polypid announces positive FDA Pre-NDA meeting minutes - marketscreener.com
PolyPid Gains FDA Support for D-PLEX100 NDA Submission - TipRanks
PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission - TipRanks
PolyPid (NASDAQ: PYPD) highlights positive FDA pre-NDA minutes for D-PLEX100 NDA path - Stock Titan
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
How institutional buying supports PolyPid Ltd. stockExit Point & Expert Approved Momentum Ideas - Newser
PolyPid stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
PolyPid stock rating reiterated at Market Outperform by Citizens By Investing.com - Investing.com India
PolyPid Expands Share Offering to Strengthen Financial Position - The Globe and Mail
PYPD ups at-the-market ordinary share program limit to $15M - Stock Titan
PolyPid (PYPD) raises ordinary share Sales Agreement capacity - Stock Titan
0.86%
자본화:
|
볼륨(24시간):